Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System
The objective was using the Essential Medicines List for children by the World Health Organization (WHO) to create a pediatric biopharmaceutics classification system (pBCS) of the oral drugs included in the Essential Medicines List by the World Health Organization and to compare our results with the...
Saved in:
Main Authors: | Jose-Manuel de (Author), Isabel Gonzalez-Alvarez (Author), Marta Gonzalez-Alvarez (Author), Andres Navarro (Author), Marival Bermejo (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug
by: Isabel Gonzalez-Alvarez, et al.
Published: (2024) -
Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019
by: Jose-Manuel de, et al.
Published: (2020) -
Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system
by: Valeria Gigante, et al.
Published: (2020) -
Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development
by: Wolk O, et al.
Published: (2014) -
Pediatric Biopharmaceutical Classification Systems (pBCS)
by: Justyna Srebro, et al.
Published: (2023)